We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

UK Clinical Trial Authorization Assessment Performance

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

From 1 November 2007, letters from the MHRA relating to clinical trial submissions will not be signed. The wording and format of letters from the MHRA relating to clinical trial submissions will also be modified from this date. This is in line with MHRA policy.

These measures of performance are intended to provide guidance to clinical trial sponsors on performance in terms of determination (acceptance, grounds for non-acceptance) for applications for clinical trial authorizations. The charts will be updated monthly to present performance over the current business year (April to March).

Historical data from implementation of the Clinical Trials Directive (1 May 2004) are also provided. As these data accumulate, the presentation will be on a five year rolling basis.

The historical data provide information on healthy volunteer and patient trials in terms of number of applications and average time to determination. The current year provides data on healthy volunteer and patient trials and, in addition, information for first time in man studies.